ATE184019T1 - Monoklonale antikörper gegen rezeptor-induzierte bindungsstellen - Google Patents

Monoklonale antikörper gegen rezeptor-induzierte bindungsstellen

Info

Publication number
ATE184019T1
ATE184019T1 AT92906797T AT92906797T ATE184019T1 AT E184019 T1 ATE184019 T1 AT E184019T1 AT 92906797 T AT92906797 T AT 92906797T AT 92906797 T AT92906797 T AT 92906797T AT E184019 T1 ATE184019 T1 AT E184019T1
Authority
AT
Austria
Prior art keywords
receptor
ribs
ligand
monoclonal antibodies
binding site
Prior art date
Application number
AT92906797T
Other languages
English (en)
Inventor
Concepcion Zamarron
Edward F Plow
Mark H Ginsberg
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of ATE184019T1 publication Critical patent/ATE184019T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT92906797T 1991-02-12 1992-02-12 Monoklonale antikörper gegen rezeptor-induzierte bindungsstellen ATE184019T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/654,839 US5372933A (en) 1988-10-03 1991-02-12 Polypeptides that mimic receptor-induced binding sites, and methods of using same

Publications (1)

Publication Number Publication Date
ATE184019T1 true ATE184019T1 (de) 1999-09-15

Family

ID=24626448

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92906797T ATE184019T1 (de) 1991-02-12 1992-02-12 Monoklonale antikörper gegen rezeptor-induzierte bindungsstellen

Country Status (12)

Country Link
US (1) US5372933A (de)
EP (1) EP0573545B1 (de)
JP (2) JP3315405B2 (de)
AT (1) ATE184019T1 (de)
CA (1) CA2103893A1 (de)
DE (1) DE69229911T2 (de)
DK (1) DK0573545T3 (de)
ES (1) ES2134799T3 (de)
GR (1) GR3031720T3 (de)
IE (1) IE920462A1 (de)
PT (1) PT100122B (de)
WO (1) WO1992014150A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051231A (en) * 1988-09-01 2000-04-18 Bayer Corporation Antiviral methods and prepations
US6143298A (en) * 1988-09-01 2000-11-07 Bayer Corporation Soluble truncated forms of ICAM-1
ES2141076T3 (es) 1988-09-01 2000-03-16 Bayer Ag Proteina del receptor de rinovirus humano que inhibe la infectividad del virus.
US6514936B1 (en) 1988-09-01 2003-02-04 Bayer Corporation Antiviral methods using human rhinovirus receptor (ICAM-1)
EP0468257B1 (de) * 1990-07-20 1999-09-01 Bayer Corporation Multimere Formen des menschlichen Rhinovirus-Rezeptorproteins
US6107461A (en) * 1990-07-20 2000-08-22 Bayer Corporation Multimeric forms of human rhinovirus receptor and fragments thereof, and method of use
US6130202A (en) * 1990-07-20 2000-10-10 Bayer Corporation Antiviral methods
US5736122A (en) * 1991-02-08 1998-04-07 Diatide, Inc. Technetium-99m labeled peptides for thrombus imaging
CA2101942C (en) * 1991-02-08 2001-01-30 Richard T. Dean Technetium-99m labeled polypeptides for imaging
US5645815A (en) * 1991-02-08 1997-07-08 Diatide, Inc. Radiolabled compounds for thrombus imaging
US5968476A (en) * 1992-05-21 1999-10-19 Diatide, Inc. Technetium-99m labeled peptides for thrombus imaging
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
DE19620443C2 (de) * 1996-05-21 1998-09-17 Rhein Biotech Proz & Prod Gmbh Verfahren zum automatischen Durchführen von Bluttests
JP2002508398A (ja) 1997-12-12 2002-03-19 ジェフリー シー． ウェイ タンパク質−タンパク質相互作用を阻害するための化合物と方法
US6623981B2 (en) 1998-01-27 2003-09-23 Bristol-Myers Squibb Company Detection of patients at risk for developing integrin antagonist/agonist mediated disease states
CA2397833A1 (en) * 2000-01-20 2001-07-26 Hadasit Medical Research Services & Development Company Ltd. Novel haptotactic peptides
DE60126078T2 (de) * 2000-05-24 2007-11-15 Ph Plate Microplate Techniques Ab Neues verfahren und vorrichtung dafür
SE0001936D0 (sv) * 2000-05-24 2000-05-24 Phplate Stockholm Ab New method and device
DE60336754D1 (de) * 2002-02-14 2011-05-26 Univ R Enzymbehandlung von nahrungsmitteln für zöliakie-sprue
US8143210B2 (en) 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
US7462688B2 (en) * 2002-05-14 2008-12-09 The Board Of Trustees Of The Leland Stanford Junior University Peptides for diagnostic and therapeutic methods for celiac sprue
AU2003303576A1 (en) * 2002-05-14 2004-07-29 The Board Of Trustees Of The Leland Stanford Junior University Endometrial genes in endometrial disorders
CA2487247A1 (en) * 2002-05-14 2003-11-27 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7265093B2 (en) * 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
US7153829B2 (en) * 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
ATE477020T1 (de) * 2002-06-07 2010-08-15 Dyax Corp Prevention und verringerung von ischemia
PT2386310T (pt) 2002-08-28 2019-02-05 Dyax Corp Métodos para preservar órgãos e tecidos
IL152609A0 (en) * 2002-11-03 2003-06-24 Hapto Biotech Inc Liposomal compositions comprising haptotactic peptides and uses thereof
EP1563300B1 (de) 2002-11-20 2012-04-18 The Board Of Trustees Of The Leland Stanford Junior University Diagnoseverfahren für sprue/zöliakie
US7579313B2 (en) 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
WO2005066202A2 (en) * 2003-12-22 2005-07-21 E.I. Du Pont De Nemours And Company Bacillus cry9 family members
US7235530B2 (en) * 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
US7807645B2 (en) * 2005-09-23 2010-10-05 The Regents Of The University Of California Method of treating degenerative disorders of the nervous system by administration of fibrinogen fragment
JP2009529542A (ja) * 2006-03-10 2009-08-20 ダイアックス コーポレーション エカランチドに関する配合物
US8778338B2 (en) * 2007-03-16 2014-07-15 The Board Of Trustees Of The Leland Stanford Junior University Combination enzyme therapy for digestion of dietary gluten
AU2010203712A1 (en) * 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
JP6037841B2 (ja) * 2010-01-06 2016-12-07 ダイアックス コーポレーション 血漿カリクレイン結合タンパク質
ES2545749T3 (es) 2010-02-22 2015-09-15 B Food Science Co., Ltd. Potenciador de la adhesión célula-célula epitelial para uso en la mejora, tratamiento y prevención de enfermedades alérgicas
AU2012204202A1 (en) 2011-01-06 2013-07-11 Dyax Corp. Plasma kallikrein binding proteins
US10428158B2 (en) 2014-03-27 2019-10-01 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
CN108602893A (zh) 2015-12-11 2018-09-28 戴埃克斯有限公司 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途
US11986536B2 (en) 2019-03-23 2024-05-21 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
EP3715375A1 (de) 2019-03-23 2020-09-30 Ablevia biotech GmbH Verbindung zur prävention oder behandlung von präeklampsie
EP3715376A1 (de) 2019-03-23 2020-09-30 Ablevia biotech GmbH Verbindung zur vorbeugung oder behandlung von myasthenia gravis
EP3715374A1 (de) 2019-03-23 2020-09-30 Ablevia biotech GmbH Verbindung zur sequestrierung von unerwünschten antikörpern in einem patienten
JP2023542389A (ja) 2020-09-23 2023-10-06 アブレヴィア バイオテック ゲーエムベーハー 自己抗体で媒介される状態の予防又は治療のための化合物
TW202228784A (zh) 2020-09-23 2022-08-01 奧地利商艾柏力維亞生技有限公司 用以於一患者中螯合非預期的抗ｐｅｇ抗體的化合物
CN116669755A (zh) 2020-09-23 2023-08-29 艾柏力维亚生技有限公司 用于增加因子viii替代疗法的效力的化合物
JP2023542390A (ja) 2020-09-23 2023-10-06 アブレヴィア バイオテック ゲーエムベーハー ウイルスベクターの有効性を増強するための化合物
US20230381334A1 (en) 2020-09-23 2023-11-30 Ablevia Biotech Gmbh Compound for the sequestration of undesirable antibodies in a patient
WO2022063880A1 (en) 2020-09-24 2022-03-31 Ablevia Biotech Gmbh Compound for the prevention or treatment of myasthenia gravis
WO2023180502A1 (en) 2022-03-24 2023-09-28 Ablevia Biotech Gmbh Compound for increasing efficacy of oncolytic viruses

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4455290A (en) * 1981-04-02 1984-06-19 Research Corporation Inhibition of fibrin polymerization by a peptide isolated from fibrin Fragment D1
EP0091760B1 (de) * 1982-04-09 1986-07-02 FUJIREBIO KABUSHIKI KAISHA also trading as FUJIREBIO INC. Anti-Immunkomplex-Antikörper und Verfahren zur Herstellung desselben
GB2161165A (en) * 1984-06-12 1986-01-08 Cambridge Patent Dev Secondary antibodies
US4820505A (en) * 1985-04-04 1989-04-11 Scripps Clinic And Research Foundation Detection of activated platelets with antibodies to thrombospondin
EP0437547B1 (de) * 1988-10-03 1999-12-29 The Scripps Research Institute Monoklonale antikörper gegen rezeptor-induzierte bindungsstellen auf liganden, die an proteine der cytoadhesin-superfamilie binden

Also Published As

Publication number Publication date
DE69229911T2 (de) 2000-01-20
EP0573545A4 (de) 1995-04-12
AU1415292A (en) 1992-09-07
GR3031720T3 (en) 2000-02-29
IE920462A1 (en) 1992-08-12
US5372933A (en) 1994-12-13
EP0573545A1 (de) 1993-12-15
PT100122A (pt) 1993-05-31
ES2134799T3 (es) 1999-10-16
JPH06506203A (ja) 1994-07-14
CA2103893A1 (en) 1992-08-13
DK0573545T3 (da) 1999-12-13
PT100122B (pt) 1999-06-30
AU649800B2 (en) 1994-06-02
EP0573545B1 (de) 1999-09-01
WO1992014150A1 (en) 1992-08-20
JP3315405B2 (ja) 2002-08-19
JP2002275196A (ja) 2002-09-25
DE69229911D1 (de) 1999-10-07

Similar Documents

Publication Publication Date Title
ATE184019T1 (de) Monoklonale antikörper gegen rezeptor-induzierte bindungsstellen
EP0575546A4 (en) Prad1 cyclin and its cdna
KR900702007A (ko) T세포 항원 수용체의 지어부위와 반응하는 단클론항체
TW221675B (de)
ATE169031T1 (de) Zellrezeptor spezifische monoklonale antikörper gegen stammzell-faktor-rezeptor
ES250504U (es) Dispositivo de construccion para sujetar un objeto de traba-jo a una estructura de hormigon.
NO172596C (no) Apolipoprotein b-spesifikke monoklonale antistoffer produsert av to nye hybridomer, anvendelse av disse og diagnostiske systemer inneholdende disse
TW272197B (de)
DK208189D0 (da) Fremgangsmaade til syntese af ferrichlorid
ATE188248T1 (de) Monoklonale antikörper gegen rezeptor-induzierte bindungsstellen auf liganden, die an proteine der cytoadhesin-superfamilie binden
ATE180788T1 (de) Polypeptide mit einer aktivität des menschlichen dopaminergischen rezeptors, deren kodierende nukleinsäuresequenzen und verwendung dieser polypeptide
SU773007A1 (ru) В жущее
ES247680U (es) Hoja bituminosa compuesta,especialmente para elementos de hermeticidad
FI101808B1 (fi) Monoklonaaliset vasta-aineet reseptori-indusoituja sitoutumiskohtia vastaan
NO177536C (no) HIV-1-relaterte polypeptider, preparat som omfatter en blanding med minst to polypeptider, samt diagnostisk system og anvendelse av et polypeptid for måling av anti-HIV-1-antistoffer
NZ228194A (en) Monoclonal antibodies which bind to the n-terminal peptide sequence of the betasubunit of human haemoglobiin
FI956041A (fi) Kompositiot ja diagnostiset menetelmät, joissa käytetään monoklonaalisia vasta-aineita CD44V6 vastaan

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee